Starling Oncology, Inc. STLN
$6.90
$0.274.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 587.24M | 545.76M | 502.73M | 461.04M | 424.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 587.24M | 545.76M | 502.73M | 461.04M | 424.38M |
| Cost of Revenue | 495.08M | 463.26M | 426.29M | 392.73M | 360.62M |
| Gross Profit | 92.17M | 82.50M | 76.44M | 68.31M | 63.75M |
| SG&A Expenses | 111.45M | 108.41M | 105.57M | 102.39M | 103.79M |
| Depreciation & Amortization | 6.81M | 6.78M | 6.94M | 7.02M | 6.87M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 613.33M | 578.45M | 538.81M | 502.14M | 471.28M |
| Operating Income | -26.09M | -32.69M | -36.08M | -41.11M | -46.90M |
| Income Before Tax | -36.29M | -43.64M | -60.74M | -66.41M | -66.02M |
| Income Tax Expenses | 0.00 | -131.00K | -131.00K | -131.00K | -131.00K |
| Earnings from Continuing Operations | -36.29 | -43.51 | -60.61 | -66.28 | -65.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.29M | -43.51M | -60.61M | -66.28M | -65.89M |
| EBIT | -26.09M | -32.69M | -36.08M | -41.11M | -46.90M |
| EBITDA | -19.28M | -25.91M | -29.14M | -34.09M | -40.04M |
| EPS Basic | -0.31 | -0.38 | -0.56 | -0.64 | -0.68 |
| Normalized Basic EPS | -0.23 | -0.28 | -0.40 | -0.46 | -0.49 |
| EPS Diluted | -0.31 | -0.38 | -0.57 | -0.65 | -0.69 |
| Normalized Diluted EPS | -0.23 | -0.28 | -0.40 | -0.46 | -0.49 |
| Average Basic Shares Outstanding | 403.76M | 393.94M | 369.23M | 343.43M | 321.48M |
| Average Diluted Shares Outstanding | 403.76M | 393.94M | 369.23M | 343.43M | 321.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |